Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C

NCT01753557 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C (CHC)

Interventions

DRUG: MP-424
DRUG: RBV
DRUG: PEG-IFN alfa-2a

Sponsor

Tanabe Pharma Corporation